Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | IGF2R | P11717 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527259 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL207380 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL207105 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL27816756 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29528060 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL2290293 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL4267711 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29527606 | 0.90 | SLC6A2 (0.44) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29527678 | 0.90 | PTPN1 (0.39) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29527771 | 0.88 | CD209 (0.38) | PTPN1CA2PTPN2KDM6BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10231907-B2 | Compositions for improving the health and appearance of skin | ALGENIST HOLDINGS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20150366791-A1 | Compositions for Improving the Health and Appearance of Skin | ALGENIST BRANDS LLC | 2015-12-24 | — | — | US | disclosed |
| US-9095733-B2 | Compositions for improving the health and appearance of skin | SOLAZYME, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8298548-B2 | Compositions for improving the health and appearance of skin | SOLAZYME, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120264177-A1 | Compositions for Improving the Health and Appearance of Skin | SOLAZYME, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2123174-A2 | Process for producing aglycon and flavor-improved food containing the aglycon by diglycosidase, and converting agent to be used in the process | Amano Enzyme Inc. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090069213-A1 | Compositions for Improving the Health and Appearance of Skin | SOLAZYME, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-7118895-B2 | Process for producing aglycon by using diglycosidase and flavor-improved food containing the aglycon and converting agent to be used in the process | AMANO ENZYME INC. (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060216281-A1 | Process for producing aglycon and flavor-improved food containing the aglycon by diglycosidase, and converting agent to be used in the process | AMANO ENZYME INC. | 2006-09-28 | — | — | US | disclosed |
| US-20030194469-A1 | Process for producing aglycon by using diglycosidase and flavor-improved food containing the aglycon and converting agent to be used in the process | AMANO ENZYME INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1270735-A1 | PROCESS FOR PRODUCING AGLYCON BY USING DIGLYCOSIDASE AND FLAVOR-IMPROVED FOOD CONTAINING THE AGLYCON AND CONVERTING AGENT TO BE USED IN THE PROCESS | Amano Enzyme Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216281-A1 | Process for producing aglycon and flavor-improved food containing the aglycon by diglycosidase, and converting agent to be used in the process | GAA, SI, MGAM | PTPN1 3248/4885CA2 169/4885PTPN2 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.